Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors
| Autor: | Brad Rice, Janean Fidel, Stacey Hansen, Joshua I. Molho, Jeffrey A. Meganck, Valorie R. Wiss, Sue E. Knoblaugh, Katie C. Kennedy, James M. Olson, William S. Dernell, Mark R. Stroud, Julia Parrish-Novak |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Diagnostic Imaging
Indocyanine Green Male Cancer Research Pathology medicine.medical_specialty Adolescent media_common.quotation_subject Cell Contrast Media Scorpion Venoms Article chemistry.chemical_compound Dogs Surgical oncology Neoplasms medicine Medical imaging Animals Humans Contrast (vision) Child Fluorescent Dyes media_common Intraoperative Care business.industry Soft tissue sarcoma Reproducibility of Results Soft tissue medicine.disease Fluorescence Disease Models Animal medicine.anatomical_structure Oncology chemistry Child Preschool Female business Indocyanine green |
| Zdroj: | Cancer Research. 75:4283-4291 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | There is a need in surgical oncology for contrast agents that can enable real-time intraoperative visualization of solid tumors that can enable complete resections while sparing normal surrounding tissues. The Tumor Paint agent BLZ-100 is a peptide–fluorophore conjugate that can specifically bind solid tumors and fluoresce in the near-infrared range, minimizing light scatter and signal attenuation. In this study, we provide a preclinical proof of concept for use of this imaging contrast agent as administered before surgery to dogs with a variety of naturally occurring spontaneous tumors. Imaging was performed on excised tissues as well as intraoperatively in a subset of cases. Actionable contrast was achieved between tumor tissue and surrounding normal tissues in adenocarcinomas, squamous cell carcinomas, mast cell tumors, and soft tissue sarcomas. Subcutaneous soft tissue sarcomas were labeled with the highest fluorescence intensity and greatest tumor-to-background signal ratio. Our results establish a foundation that rationalizes clinical studies in humans with soft tissue sarcoma, an indication with a notably high unmet need. Cancer Res; 75(20); 4283–91. ©2015 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|